None of that supports your bullshit that observational studies are not valid or provide evidence of efficacy regularly used to guide treatment, or addresses the real strengths and weaknesses of RCT's under various conditions. Whether it's studies of infectious disease or heart or liver disease doesn't matter. It's the underlying statistical math principles that are clearly explained. Your attack on observational studies in this context with the observed size of treatment effects is reckless and wrong. get your shit together or shut the fuck up about it.
And the Yale peers aren't talking about observational studies vs RCT's. The unfortunate letter from other Yale peers was penned Aug 4th. A lot more has happened in the world since then. HCQ got thrust outside the medical/scientific arena into politics and mass marketing, so Yale peers stating his views don't reflect the views of Yale Med et al is appropriate. Dr. McCullough makes the disclaimer that his views aren't representative of Baylor Hospital proper, no letter written. But the Yale peer letter also parses and gives a now familiar incomplete account:
"In fact, rigorously-conducted clinical trials have found that HCQ is not effective as an early prophylactic therapy in preventing illness due to COVID-19 in people exposed to the virus. Furthermore, HCQ, alone or together with the antibiotic, azithromycin, has not been shown to be effective in improving the clinical status of patients with COVID-19."
For early outpatient treatment, they refer to one study only (Boulware USA) -for prophylaxis against the presence of virus after an exposure, not to prevent hospitalization and death in infected cases treated early. The significance of that distinction is huge, and completely lost in in the Yale letter. That level of misrepresentation and misunderstanding is a giant fucking problem if used to claim early outpatient treatment is ineffective. HCQ alone or together at that time "has not been shown to be effective in improving clinical status of patients"? Not progressing to hospitalization and death, truly, is not "improving clinical status". It's a true statement in a context of study terms. But it's also a shitty attempt at parsing they're engaging in. A near 50% reduction in need for hospitalization and resultant death does not mean improving clinical status by comparison in parallel with control, it means (in study terms) that you don't get worse. In this case treatment and control have similar clinical pictures for a period, then control crashes and dies, but the treatment group shows no evidence of improving clinical status despite being alive and still able to breathe. Do you need more explanation, knucklehead?
We've got multiple effective options for early outpatient treatment - ivermectin is shaping up to be a silver bullet- but at the end of the day the US bodies at the federal level failed to do the studies needed to map it out. period. People got blinded or brainwashed while others were gaming to profit by ignoring the reality of these options in favor of vastly more expensive novel therapeutics.